A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

NCT04970901 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma

Interventions

DRUG: Loncastuximab Tesirine
DRUG: Polatuzumab Vedotin
DRUG: Glofitamab
DRUG: Mosunetuzumab
DRUG: Obinutuzumab

Sponsor

ADC Therapeutics S.A.